Latest Breaking News On - Kidney protection with empagliflozin - Page 1 : comparemela.com

The SGLT2 inhibitor empagliflozin (Jardiance) was approved by European regulators for treating adults with chronic kidney disease. The FDA is reviewing a new drug application for this indication.

Dapagliflozin farxigaCanagliflozin invokanaBoehringer ingelheimJanssen pharmaceuticalsEuropean commissionEuropean unionDrug administrationObesity global medical affairsKidney protection with empagliflozinLeonard glassDapagliflozin also approvedKidney diseaseChronic renal failureHronic kidney failureHronic kidney disease ckdChronic kidney disease